Literature DB >> 11773288

Traditional and newer pathologic factors.

S J Schnitt1.   

Abstract

There has long been a pressing clinical need to identify prognostic and predictive factors for patients with breast cancer. Although numerous candidate biological and molecular markers have been identified during the last two decades, traditional factors such as lymph node status, tumor size, histologic type, histologic grade, and hormone receptor status remain the most useful indicators of prognosis and therapeutic response. A major obstacle to the translation of research advances into clinically useful prognostic and predictive markers has been the considerable methodologic variability used in the evaluation of the newer markers. It is now generally accepted that, to be useful in patient management, a putative prognostic or predictive marker must have clinical importance, independence, significance, and standardization with regard to methods, interpretation, and reporting. It is hoped that recognition and adoption of these criteria will serve to clarify the value of newer biologic and molecular markers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11773288     DOI: 10.1093/oxfordjournals.jncimonographs.a003456

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  14 in total

Review 1.  Genomic medicine: genetic variation and its impact on the future of health care.

Authors:  Huntington F Willard; Misha Angrist; Geoffrey S Ginsburg
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 2.  Statistical consideration for clinical biomarker research in bladder cancer.

Authors:  Shahrokh F Shariat; Yair Lotan; Andrew Vickers; Pierre I Karakiewicz; Bernd J Schmitz-Dräger; Peter J Goebell; Nuria Malats
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

3.  Individualized Survival and Treatment Response Predictions in Breast Cancer Patients: Involvements of Phospho-EGFR and Phospho-Her2/neu Proteins.

Authors:  Lan Guo; Jame Abraham; Daniel C Flynn; Vincent Castranova; Xianglin Shi; Yong Qian
Journal:  Open Clin Cancer J       Date:  2008-05-27

4.  Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression.

Authors:  Alessandro Sgambato; Mario Migaldi; Micaela Montanari; Andrea Camerini; Andrea Brancaccio; Giulio Rossi; Rodolfo Cangiano; Carmen Losasso; Giovanni Capelli; Gian Paolo Trentini; Achille Cittadini
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

5.  A population-based gene signature is predictive of breast cancer survival and chemoresponse.

Authors:  Shruti Rathnagiriswaran; Ying-Wooi Wan; Jame Abraham; Vincent Castranova; Yong Qian; Nancy L Guo
Journal:  Int J Oncol       Date:  2010-03       Impact factor: 5.650

6.  Fischer's score criteria correlating with histopathological prognostic factors in invasive breast cancer.

Authors:  V Girardi; G Carbognin; L Camera; M Tonegutti; F Bonetti; E Manfrin; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2009-09-22       Impact factor: 3.469

7.  Prediagnostic use of hormone therapy and mortality after breast cancer.

Authors:  Polly A Newcomb; Kathleen M Egan; Amy Trentham-Dietz; Linda Titus-Ernstoff; John A Baron; John M Hampton; Meir J Stampfer; Walter C Willett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

8.  Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.

Authors:  Sebastian F Schoppmann; Guenther Bayer; Klaus Aumayr; Susanne Taucher; Silvana Geleff; Margaretha Rudas; Ernst Kubista; Hubert Hausmaninger; Hellmut Samonigg; Michael Gnant; Raimund Jakesz; Reinhard Horvat
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 9.  Axillary surgery in breast cancer patients.

Authors:  A Millet; C A Fuster; A Lluch; F Dirbas
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.405

10.  Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.

Authors:  Douglas T Ross; Chung-Yeul Kim; Gong Tang; Olga L Bohn; Rodney A Beck; Brian Z Ring; Robert S Seitz; Soonmyung Paik; Joseph P Costantino; Norman Wolmark
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.